ONCT — Oncternal Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $27.82m
- -$6.43m
- $0.79m
- 18
- 19
- 82
- 34
Annual balance sheet for Oncternal Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 20.1 | 117 | 90.8 | 63.7 | 34.3 |
| Net Total Receivables | — | — | — | 0.178 | 0.632 |
| Prepaid Expenses | |||||
| Total Current Assets | 20.8 | 118 | 92.9 | 67.3 | 36.1 |
| Net Property, Plant And Equipment | 0.19 | 0.04 | 0.075 | 0.087 | 0.258 |
| Other Long Term Assets | |||||
| Total Assets | 21.7 | 119 | 93.6 | 68.7 | 36.7 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 7.34 | 5.86 | 5.46 | 7.68 | 5.2 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 7.43 | 5.86 | 5.46 | 7.68 | 6.68 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 14.3 | 113 | 88.1 | 61 | 30.1 |
| Total Liabilities & Shareholders' Equity | 21.7 | 119 | 93.6 | 68.7 | 36.7 |
| Total Common Shares Outstanding |